BLA 125477 · Eli Lilly and CO
Cyramza
Ramucirumab · Injection · Vascular Endothelial Growth Factor Receptor 2 Antagonist
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Apr 21, 2014
Approved uses
8
Original approval plus efficacy supplements
Registered trials
178
28 Phase 3, 25 recruiting
FAERS reports
6,320
5,943 serious, 1,693 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 9, 2026.
CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal...
Mechanism: Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 7, 2025 Supplement 49 · Efficacy · priority review OrphanLabelLetter
- Jan 27, 2025 Supplement 48 · Efficacy OrphanLabelLetter
- May 29, 2020 Supplement 34 · Efficacy LetterLabel
- May 10, 2019 Supplement 29 · Efficacy OrphanLetter
- Apr 24, 2015 Supplement 11 · Efficacy LetterLabel
- Dec 12, 2014 Supplement 7 · Efficacy · priority review LabelLetter
- Nov 5, 2014 Supplement 2 · Efficacy OrphanLabelLetter
- Apr 21, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelSummary Review
2 products under this application
- CYRAMZA · RAMUCIRUMAB 500MG/50ML · INJECTABLE, INJECTION · Prescription
- CYRAMZA · RAMUCIRUMAB 100MG/10ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ramucirumab" as an intervention, any sponsor and status, largest first.
EMD Serono Research & Development Institute, Inc.Industry
NCT01772004 · 1,756 participants · Start Jan 31, 2013 · Primary completion Dec 16, 2019
Drug: Avelumab · For: Solid Tumors
Sites: Goodyear, Arizona; Scottsdale, Arizona; Rogers, Arkansas · 74 sites in all
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based ChemotherapyPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01168973 · 1,253 participants · Start Dec 2010 · Primary completion Dec 2013
Drug: Ramucirumab; Placebo (for Ramucirumab) and 1 more · For: Non-Small Cell Lung Cancer
Sites: Phoenix, Arizona; Sedona, Arizona; Fayetteville, Arkansas · 231 sites in all
- Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00703326 · 1,144 participants · Start Aug 6, 2008 · Primary completion Mar 31, 2013
Drug: ramucirumab (IMC-1121B); docetaxel · For: Breast Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 232 sites in all
- A Study in Second Line Metastatic Colorectal CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01183780 · 1,072 participants · Start Dec 2, 2010 · Primary completion Jul 17, 2014
Drug: Ramucirumab; Placebo and 3 more · For: Colorectal Cancer
Sites: Sedona, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 213 sites in all
- AB122 Platform StudyRecruiting
Taiho Pharmaceutical Co., Ltd.Industry
NCT04999761 · 917 participants (planned) · Start Jun 1, 2021 · Primary completion Jun 2027
Drug: AB122; AB122 and 19 more · For: Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer and 6 more
Sites: Aichi, Japan; Chiba, Japan; Ehime, Japan · 9 sites in all
- Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT05633602 · 838 participants · Start Mar 14, 2023 · Primary completion Nov 26, 2025
Drug: Chemotherapy; Pembrolizumab and 1 more · For: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 566 sites in all
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05719558 · 798 participants (planned) · Start Mar 13, 2023 · Primary completion Apr 30, 2030
Drug: ASP1002; Bevacizumab and 10 more · For: Advanced Solid Tumors
Sites: New Haven, Connecticut; Plainville, Connecticut; Gainesville, Florida · 15 sites in all
- A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric AdenocarcinomaPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01170663 · 665 participants · Start Dec 2010 · Primary completion Jul 2013
Drug: Ramucirumab (IMC-1211B) DP; Placebo and 1 more · For: Gastric Cancer
Sites: Burbank, California; Los Angeles, California; San Francisco, California · 167 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression817
- death614
- interstitial lung disease301
- neutropenia268
- febrile neutropenia265
- decreased appetite234
- diarrhoea229
- off label use218
- nausea209
- disease progression204
- fatigue203
- hypertension194
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 5 |
| 2012 | 17 |
| 2013 | 13 |
| 2014 | 131 |
| 2015 | 405 |
| 2016 | 471 |
| 2017 | 621 |
| 2018 | 687 |
| 2019 | 630 |
| 2020 | 519 |
| 2021 | 628 |
| 2022 | 533 |
| 2023 | 502 |
| 2024 | 474 |
| 2025 | 386 |
| 2026 | 298 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cyramza (Ramucirumab)
2024 spending
$5.0M
Beneficiaries
106
448 claims
Per beneficiary
$47,536
$143.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,738,813 |
| 2021 | $3,028,499 |
| 2022 | $3,653,499 |
| 2023 | $3,797,757 |
| 2024 | $5,038,823 |
Part B: Cyramza (Ramucirumab) · HCPCS J9308
2024 spending
$138M
Beneficiaries
3,080
14,487 claims
Per beneficiary
$44,726
2024 ASP limit $70.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $130,155,956 |
| 2021 | $116,423,797 |
| 2022 | $122,952,659 |
| 2023 | $133,899,400 |
| 2024 | $137,755,156 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Shitara K, Van Cutsem E, Gümüş M, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
Haber PK, Puigvehí M, Castet F, et al. · Gastroenterology 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB, Ciuleanu TE, Arrieta O, et al. · Lancet 2014 · Clinical Trial, Phase III, Multicenter Study
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H, Muro K, Van Cutsem E, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shitara K, Doi T, Dvorkin M, et al. · Lancet Oncol 2018 · Clinical Trial, Phase III, Multicenter Study
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. · J Clin Oncol 2023 · Systematic Review, Practice Guideline
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.